CN1383851A - Lung cancer treating medicine and its prepn - Google Patents
Lung cancer treating medicine and its prepn Download PDFInfo
- Publication number
- CN1383851A CN1383851A CN 02108618 CN02108618A CN1383851A CN 1383851 A CN1383851 A CN 1383851A CN 02108618 CN02108618 CN 02108618 CN 02108618 A CN02108618 A CN 02108618A CN 1383851 A CN1383851 A CN 1383851A
- Authority
- CN
- China
- Prior art keywords
- herba
- radix
- lung cancer
- powder
- cancer drugs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The lung cancer treating medicine is prepared with sixangular dysosma rhizome, toad skin, astragalus root, mockstrawberry, fiveleaf akebia fruit and other four Chinese medicinal materials and through and frying, honey frying, wind drying, crushing, solvent extracting, mixing, cooking and sterilizing. It is prepared to medicine powder or pills, and has unique recipe and preparation process and obvious curative effect.
Description
The present invention relates to a kind of treatment lung cancer drugs,, the invention still further relates to the preparation method of this medicine specifically with the Chinese patent medicine of herbal raw material preparation.
Pulmonary carcinoma is one of worldwide common malignancy, and serious threat human beings'health and life, the sickness rate of pulmonary carcinoma and mortality rate all rise with surprising rapidity.
Pulmonary carcinoma is the pulmonary carcinoma common sympton bitterly, many because cancerous protuberance pressuring nerve and adjacent tissue, cause that surrounding tissue ischemia, necrosis or cancer cell infiltration blood vessel, lymphoid tissue cause the quiet blood stasis of arterial occlusion, swelling, inflammatory reaction to stimulate thoracic wall, blood wall neural sensor and cause, pulmonary carcinoma cancer pain can occur in early days, be common in peripheral type carcinoma of lung, be first or unique symptom sometimes.To late period, lung cancer tumor mostly is the intractable distending pain, and accompanies a series of symptom of lung system.
The primary disease Drug therapy is run into following thorny problem both at home and abroad at present:
Chemicals and interferon therapy pulmonary carcinoma must have certain effect, but toxic side effects is big, feeling sick, vomitting can appear in the patient who has, alopecia, long-term anorexia even to side effect such as renal function injury, though the Chinese patent medicine of some treatment pulmonary carcinoma is also arranged, because drug effect is slow, and effect is not fairly obvious, so be difficult to control the characteristic of disease development.
The object of the present invention is to provide a kind of effect with stronger inhibition tumor cell, and can improve immune function of human body, promote lymphoblastic conversion, strengthen the reticuloendothelial system function, improve the generation of immune globulin, the enhancing patient does condition of disease power and palliates the agonizing sufferings, and prolongs the treatment lung cancer drugs of life.
Another object of the present invention provides the preparation method of this treatment lung cancer drugs Neo-Confucianism.
Solution of the present invention is based on motherland's medical science to pathogenetic understanding of pulmonary carcinosis and Therapeutic Principle, filters out removing toxic substances and promoting subsidence of swelling, tonifying Qi and lifting yang, promoting pus discharge and tissue regeneration strengthening, heat-clearing and toxic substances removing, blood circulation promoting and blood stasis dispelling, cool seroma, depressed liver-energy dispersing and QI regulating eliminating stagnation, eliminating evil detoxifcation is played, blood stasis-eliminating and stagnation-dissipating, anticancer merit altogether by full side.
Medicine of the present invention is made (consumption is a weight portion) by following component
Radix et Rhizoma Dysosmatis 5～25 dry maxima skins 5～15 Radixs Astragali 15～30
Herba Duchesneae Indicae grass 15～30 Fructus Akebiaes 15～30 Herba Scutellariae Barbataes 10～25
Herba Houttuyniae 10～25 Rhizoma Paridis 10～20 Radix Salviae Miltiorrhizaes 10～25
Formula optimization weight (part) ratio range of preparation medicine of the present invention is
Radix et Rhizoma Dysosmatis 10～25 dry maxima skins 12～15 Radixs Astragali 20～30
Herba Duchesneae Indicae grass 20～30 Fructus Akebiaes 20～30 Herba Scutellariae Barbataes 15～20
Herba Houttuyniae 15～20 Rhizoma Paridis 15～20 Radix Salviae Miltiorrhizaes 15～20
The good weight of the amount of medicine of the present invention (part) proportional quantity
Radix et Rhizoma Dysosmatis 10 dry maxima skins 12 Radixs Astragali 30 Herba Duchesneae Indicaes grass 30 Fructus Akebiaes 30
Herba Scutellariae Barbatae 15 Herba Houttuyniae 15 Rhizoma Paridis 15 Radix Salviae Miltiorrhizaes 15
Each above-mentioned component is made medicine production method of the present invention is:
1, gets Radix et Rhizoma Dysosmatis drying and crushing to 120 order fine powder earlier;
2, Radix Salviae Miltiorrhizae is broken into 120 order fine powders with the Radix et Rhizoma Dysosmatis processing powder after infusion;
3, get the Radix Astragali and after infusion, be broken into 120 order fine powders with Fructus Akebiae processing;
4, Herba Scutellariae Barbatae, Rhizoma Paridis, the air-dry 120 order fine powders that are ground into of Herba Duchesneae Indicae grass;
5, with above-mentioned whole powder components by after the described mixed, under 100 ℃～110 ℃, carried out the ripening sterilization treatment 10-30 minute, the powder medicine of the pulmonary carcinosis that can obtain medical treatment.
The ripening disinfecting action here is to adopt stage by stage or intensification ripening sterilization, and insulation is incubated 5 minutes, 110 ℃ down for 15 minutes, 105 ℃ and is incubated 10 minutes down under 100 ℃, and the ripening bacterium time is 15-30 minute, and the powder after the maturation process also can be processed as red ball.
An important feature of the present invention is to contain in the described medicament at pulmonary carcinoma, the high effective constituent of cancer therapy drug.
Radix et Rhizoma Dysosmatis: nature and flavor hardship, suffering, flat.Go into the heart, lung, kidney channel, effect heat-clearing and toxic substances removing, this product extract podophyllotoxin, deoxidation podophyllotoxin, Podophyllinic acid-2 acethydrazide have antitumaous effect, and podophyllotoxin can suppress the cell mitosis in mid-term, to multiple animal tumor, watt gram cancer W
256, sarcoma S
180The obvious suppression effect is arranged.Its anticancer mechanism is to make cell division stop at mid-term, and to acute monocytic leukemia and acute myeloblastic leukemia, Hodgkin, malignant lymphoma, breast carcinoma, minicell lung bronchogenic carcinoma all have inhibitory action.
Dry maxima skin: pungent in flavor and cool in property, the effect heat-clearing and toxic substances removing contains bufotalin, chemical analysis such as cinobufagin, bufalin, bufochrome.Cutis Bufonis extract is to tumor S in the mice
180, rabbit BP tumor is effective, and there are inhibitory action in cardiotonic glycoside in the Cutis Bufonis and glycoside unit to the He12-S3 tumor cell.
The Radix Astragali: nature and flavor are sweet, warm, go into lung, spleen channel, attack the effect invigorating QI to consolidate the body surface resistance, and the diuresis poison holding contains astragalin, daucosterol, astragalus polysaccharides, chemical analysis such as Mao Ruiyi allusion quotation ketone.Anticancer pharmacology is: experiment in the body, Radix Astragali hot water extractum is to murine sarcoma S
180Suppression ratio is 41.7%, the Radix Astragali is 12.25% to human lung adenocarcinoma SPC-A-1 cell proliferation index suppression ratio, bring out in the rat pulmonary carcinoma process with the turbid solution of MCA iodine, with Radix Astragali injection carrying out inhibition test, it is 16.28% that Radix Astragali group is sent out the cancer rate, it is 51.52%, two group of difference highly significant that matched group is sent out the cancer rate.
The Herba Duchesneae Indicae grass: nature and flavor are sweet, sour, cold, go into lung, liver, large intestine channel, and the effect clearing away heat and cooling blood contains flavonoid glycoside, chemical analysis such as triterpenoid saponin.Anticancer pharmacology: when in vitro tests, Herba Duchesneae Indicae grass are carried thing and be equivalent to 5mgml, 10mgml, 15mgml, growth of cancer cells is had stronger depression effect, can make cancerous cell completely lose fertility in 48 hours with Herba Duchesneae Indicae grass 15mgml effect.
Fructus Akebiae: nature and flavor are sweet, cold, go into liver, stomach warp, and function is soothing liver-QI stomach function regulating, promoting blood circulation and stopping pain, inducing diuresis for treating stranguria syndrome, contains chemical analysis such as Caulis Hederae Sinensis soap bag glycoside unit, oleanolic acid, akebin.Anticancer pharmacology: the inside and outside screening of animal body has inhibitory action to tumor cell, to murine sarcoma S
180Sarcoma S
37Inhibitory action is arranged, and is 50%～70% to the suppression ratio of human cervical carcinoma cell JTC-26.
Herba Scutellariae Barbatae: nature and flavor suffering, hardship, cold, go into lung, liver, kidney channel, the effect heat-clearing and toxic substances removing, the blood stasis dispelling diuresis contains carthamin, different from chemical analysis such as florigen, the plain glycoside of Radix Scutellariae, B-sitosterol, stearic acid.Anticancer pharmacology: half very strong antimutagenic effect of colored tool is one of anticancer mechanism.But water extract dosage relies on ground suppresses flavacin B
1Return to become clump count, have remarkable effect, and can obviously suppress flavacin B
1Combine with DNA, by certain purge mechanism performance antimutagenic effect.
Herba Houttuyniae: the nature and flavor suffering, be slightly cold, go into lung meridian, effect heat-clearing and toxic substances removing, the pain that disappears evacuation of pus, inducing diuresis for treating stranguria syndrome.Anticancer pharmacology: the effect that the research neo-houttuyninum is grown in the mice body to mice Emhorn ascites cells and to cancerous cell in the influence of CAMP level, knot is tabled look-up bright behind the neo-houttuyninum of different time by the different dosage of mouse peritoneal injection, the ascites volume of tumor animal, cancerous cell sum and cancerous cell di all have obvious reduction, and the CAMP level has and increases in the cancerous cell, especially with administration 34mg/kg body weight group These parameters is had more obvious influence, the effect that the prompting neo-houttuyninum suppresses ehrlich carcinoma may be relevant with CAMP level in the raising cancerous cell.
Radix Salviae Miltiorrhizae: the nature and flavor hardship, be slightly cold, go into the heart, lung meridian, the effect stasis-dispelling and pain-killing.Contain chemical analysis such as TANSHINONES, miltirone, different Radix Salviae Miltiorrhizae ethanol, Radix Salviae Miltiorrhizae lactone.Anticancer pharmacology: Radix Salviae Miltiorrhizae can prolong the time-to-live of Ehrlich ehrlich ascites carcinoma mice, uses ehrlich carcinoma, hepatocarcinoma, sarcoma S
180Carry out zoopery with leukemia L615 and show that Radix Salviae Miltiorrhizae has potentiation to the active anticancer of camptothecine.
Rhizoma Paridis: the nature and flavor hardship, be slightly cold, go into lung, Liver Channel, the pain relieving of effect clearing heat, releasing toxin, removing swelling contains paridin, potato Saponin etc.Anticancer pharmacology: Rhizoma Paridis is to tumor S in the mice
180, sarcoma S
37, the solid type tumor all has inhibitory action, experiment has the inhibition effect to animal tumor in Rhizoma Paridis n-butanol extracting liquid (total Saponin) body.
For showing the therapeutic effect of medicine of the present invention to pulmonary carcinoma, the present invention not only has the effect of stronger inhibition tumor cell, and can improve immune function of human body, strengthen patient's resistance against diseases, also do not have gastrointestinal upset should or vomiting reaction, also harmless to hemopoietic function, treat with the present invention that pulmonary carcinoma 100 examples are province, city-level hospital chest x-ray sheet and pathological examination confirms, scale cancer 43 examples wherein, adenocarcinoma 35 examples do not divide cancer 22 examples.Survival rate 37 examples more than 5 years as a result, survival rate 16 examples more than 3 years, survival rate 7 examples more than 2 years, survivor's 5 examples more than 1 year.
Instructions of taking: it is for oral administration that powder is obeyed three boiled water bubbles 10-15 minute 25 gram/next day, and 10 days is a course of treatment
The present invention is further described below in conjunction with embodiment:
Take by weighing raw material (gram) by following proportioning
Radix et Rhizoma Dysosmatis 50 dry maxima skins 60 Radixs Astragali 150 Herba Duchesneae Indicaes grass 150 Fructus Akebiaes 150
Herba Scutellariae Barbatae 75 Herba Houttuyniae 75 Rhizoma Paridis 75 Radix Salviae Miltiorrhizaes 75
Each above-mentioned component is made medicine production method of the present invention is:
1, gets Radix et Rhizoma Dysosmatis 50 gram drying and crushing to 120 order fine powders earlier;
2, Radix Salviae Miltiorrhizae 75 grams are broken into 120 order fine powders with the Radix et Rhizoma Dysosmatis processing powder after infusion;
3, get the Radix Astragali 150 grams and after infusion, be broken into 120 order fine powders with Fructus Akebiae 150 gram processing;
4, with Herba Scutellariae Barbatae 75 grams, Rhizoma Paridis 75 grams, the air-dry 120 order fine powders that are ground into of Herba Duchesneae Indicae grass 150 grams;
5, with above-mentioned whole powder components by after the described mixed, under 100 ℃～110 ℃, carried out the ripening sterilization treatment 10～30 minutes, the powder medicine of the pulmonary carcinosis that can obtain medical treatment.
The ripening disinfecting action here is to adopt stage by stage or intensification ripening sterilization, and insulation is 10 minutes under 15 minutes, 105 ℃ of insulations under 100 ℃ are incubated 5 minutes, 110 ℃, and the ripening bacterium time is 15～30 minutes, and the powder after the maturation process also can be processed as red ball.
Claims (8)
1, a kind of treatment lung cancer drugs is characterized in that it is medicament Radix et Rhizoma Dysosmatis 10～25 dry maxima skins 5～15 Radixs Astragali 15～30 Herba Duchesneae Indicae grass 15～30 Fructus Akebiaes 15～30 Herba Scutellariae Barbataes 15～20 Herba Houttuyniae 10～25 Rhizoma Paridis 15～20 Radix Salviae Miltiorrhizaes of being made by the following weight proportion raw material 15～20
2, treatment lung cancer drugs according to claim 1 is characterized in that wherein the weight proportion of each raw material is Radix et Rhizoma Dysosmatis 10～25 dry maxima skins 12～15 Radixs Astragali 20～30 Herba Duchesneae Indicae grass 20～30 Fructus Akebiaes 20～30 Herba Scutellariae Barbataes 15～20 Herba Houttuyniae 15～20 Rhizoma Paridis 15～20 Radix Salviae Miltiorrhizaes 15～20
3, want 1 to ask described treatment lung cancer drugs according to right, it is characterized in that wherein the weight proportion of each raw material is Radix et Rhizoma Dysosmatis 10 dry maxima skins 12 Radixs Astragali 30 Herba Duchesneae Indicaes grass 30 Fructus Akebiaes 30 Herba Scutellariae Barbataes 15 Herba Houttuyniae 15 Rhizoma Paridis 15 Radix Salviae Miltiorrhizaes 15
4,, it is characterized in that described medicament is a said dosage form on any pharmaceutics according to claim 1,2 or 3 described treatment lung cancer drugs.
5, treatment lung cancer drugs according to claim 4, its feature is powder or red ball in described medicament.
6, the preparation method of treatment lung cancer drugs according to claim 5 is characterized in that getting earlier Bufo siccus, removes a roguing pawl, is cut into small pieces; Get sand and put in the pot with high heat that the heating back adds clean Bufo siccus piece, take out when stirring to little coke yellow foaming, sieve shakeout cools and is crushed to 120 order fine powders immediately; Radix Salviae Miltiorrhizae section, add quantitative yellow wine mix white, stewing slightly profit, treat that wine is exhausted after, put in the parch container, with the slow fire heating, fry and do, take out the cold of drying in the air, be crushed to 120 order fine powders with Radix et Rhizoma Dysosmatis (dry product), get Radix Astragali decontamination, clean and cut sheet, drying; After getting refined honey and adding certain amount of boiling water dilution, add astragalus mongholicus tablet and mix thoroughly, stewing slightly; Put in the medicine cookeding pot, with the slow fire heating, frying tack-free to buff is degree, takes out and puts deeply; Promptly be crushed to fine powder on the 129th with Fructus Akebiae; Get Herba Houttuyniae, Herba Scutellariae Barbatae, Rhizoma Paridis, the Herba Duchesneae Indicae grass is ground into fine powder on the 120th after air-dry; Above-mentioned whole powder components by after the described mixed, are carried out ripe, sterilization treatment 10～30 minutes under 100 ℃～110 ℃ temperature, make powder.
7, the preparation method of treatment pulmonary carcinoma powder according to claim 6 is characterized in that wherein the ripening disinfecting action is to adopt stage by stage to carry out, the ripening sterilization, and temperature is from 100 ℃～110 ℃, and total curing time is 15～30 minutes.
8, the preparation method of treatment pulmonary carcinoma powder according to claim 7 is characterized in that ripening disinfecting action wherein is that the fine powder that will mix is incubated 15 minutes down at 100 ℃, and 105 ℃ of insulations were raised to 110 ℃ of insulations 10 minutes in 5 minutes again.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02108618 CN1383851A (en) | 2002-04-03 | 2002-04-03 | Lung cancer treating medicine and its prepn |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02108618 CN1383851A (en) | 2002-04-03 | 2002-04-03 | Lung cancer treating medicine and its prepn |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1383851A true CN1383851A (en) | 2002-12-11 |
Family
ID=4740346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02108618 Pending CN1383851A (en) | 2002-04-03 | 2002-04-03 | Lung cancer treating medicine and its prepn |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1383851A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101181478B (en) * | 2007-12-05 | 2010-09-29 | 王芳 | Chinese medicine for curing lung cancer and mammary cancer |
| CN102247337A (en) * | 2011-06-02 | 2011-11-23 | 陈彦 | Bufotalin dry powder inhalers and preparation method as well as application thereof |
| CN102302476A (en) * | 2011-06-02 | 2012-01-04 | 张振海 | Dehydrobufotenine dry power inhaler and preparation method and application thereof |
-
2002
- 2002-04-03 CN CN 02108618 patent/CN1383851A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101181478B (en) * | 2007-12-05 | 2010-09-29 | 王芳 | Chinese medicine for curing lung cancer and mammary cancer |
| CN102247337A (en) * | 2011-06-02 | 2011-11-23 | 陈彦 | Bufotalin dry powder inhalers and preparation method as well as application thereof |
| CN102302476A (en) * | 2011-06-02 | 2012-01-04 | 张振海 | Dehydrobufotenine dry power inhaler and preparation method and application thereof |
| CN102247337B (en) * | 2011-06-02 | 2013-03-13 | 陈彦 | Bufotalin dry powder inhalers and preparation method as well as application thereof |
| CN102302476B (en) * | 2011-06-02 | 2013-09-25 | 张振海 | Dehydrobufotenine dry power inhaler and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102327544A (en) | Traditional Chinese medicinal composition for treating cancer | |
| CN103386022B (en) | Chinese medicine composition for treating tuberculous pleurisy | |
| CN101711848B (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
| CN115463187A (en) | Application of anticancer composition in preparation of medicine for treating cancer | |
| CN1383851A (en) | Lung cancer treating medicine and its prepn | |
| CN1990033A (en) | Drug for treating hypertension, dense blood and arteriosclerosis | |
| CN104623414A (en) | Traditional Chinese medicine composition for treating nutritional obesity | |
| CN101254241B (en) | Healing composition for treating wart | |
| CN1158091C (en) | Chinese medicine composition for treating lung cancer | |
| CN112826904A (en) | Medicine for quickly treating hyperplasia of mammary glands | |
| CN1159054C (en) | Tongfuzhixie preparation | |
| CN103028028B (en) | Traditional Chinese medicine agent for treating primary hepatic carcinoma | |
| CN1242772C (en) | Chinese medicine for hemorrhoid | |
| CN102274465A (en) | Traditional Chinese medicine for treating acnes | |
| CN101530589B (en) | Chinese medicinal preparation for treating cancers | |
| CN101721610B (en) | Medicine for treating tumors | |
| CN105535710A (en) | Medicine composition for assisting in recovery after tumor radiotherapy and preparation method thereof | |
| CN1092969C (en) | Anticancer Chinese medicine | |
| CN104984261A (en) | Traditional Chinese medicine composition for treating liver-qi attacking stomach type gastral cavity pain | |
| CN1118262A (en) | Compounded composition for cancers | |
| CN108186972A (en) | Attenuation synergistic tumor suppression prescription and application | |
| CN111643547A (en) | Composition and preparation method thereof | |
| CN100336555C (en) | Danshen capsule for antitumour and its preparation technology | |
| CN114869987A (en) | A Chinese medicinal composition for preventing and treating hepatocarcinoma | |
| CN117883544A (en) | Traditional Chinese medicine composition for treating chronic atrophic gastritis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |